The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target
Open accessAbstract
The reception and integration of the plethora of signals a cell receives from its microenvironment determines the cell's fate. CD44 functions as a receptor for hyaluronan and many other extracellular matrix components, as well as a cofactor for growth factors and cytokines, and thus, CD44 is a signaling platform that integrates cellular microenvironmental cues with growth factor and cytokine signals and transduces signals to membrane-associated cytoskeletal proteins or to the nucleus to regulate a variety of gene expression levels related to cell-matrix adhesion, cell migration, proliferation, differentiation, and survival. Accumulating evidence indicates that CD44, especially CD44v isoforms, are cancer stem cell (CSC) markers and critical players in regulating the properties of CSCs, including self-renewal, tumor initiation, metastasis, and chemoradioresistance. Furthermore, there is ample evidence that CD44, especially CD44v isoforms, are valuable prognostic markers in various types of tumors. Therefore, therapies that target CD44 may destroy the CSC population, and this holds great promise for the cure of life-threatening cancers. However, many challenges remain to determining how best to use CD44 as a biomarker and therapeutic target. Here we summarize the current findings concerning the critical role of CD44/CD44v in the regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer. We also discuss the current challenges and future directions that may lead to the best use of CD44/CD44v for clinical applications. Significance: Mounting evidence indicates that cancer stem cells (CSCs) are mainly responsible for cancer aggressiveness, drug resistance, and tumor relapse. CD44, especially CD44v isoforms, have been identified as CSC surface markers for isolating and enriching CSCs in different types of cancers. The current findings concerning the critical role of CD44/CD44v in regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer are summarized. The current challenges and future directions that may lead to best use of CD44/CD44v for clinical applications are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chetty, C., Vanamala, S. K., Gondi, C. S., Dinh, D. H., Gujrati, M., & Rao, J. S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.008 · Cited by 133
RetractedProspective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
CD44 is the principal cell surface receptor for hyaluronate
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., & Seed, B. (1990) · Cell · doi:10.1016/0092-8674(90)90694-a · Cited by 2,438
CD44: From adhesion molecules to signalling regulators
Ponta, H., Sherman, L., & Herrlich, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1004 · Cited by 2,386
LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan
Banerji, S., Ni, J., Wang, S.-X., Clasper, S., Su, J., Tammi, R., Jones, M., & Jackson, D. G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.4.789 · Cited by 1,583
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557
Oxygen in Stem Cell Biology: A Critical Component of the Stem Cell Niche
Mohyeldin, A., Garzón-Muvdi, T., & Quiñones-Hinojosa, A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.007 · Cited by 1,535
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Interactions between cancer stem cells and their niche govern metastatic colonization
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., & Huelsken, J. (2012) · Nature · doi:10.1038/nature10694 · Cited by 1,339
The metastatic niche: adapting the foreign soil
Psaila, B., & Lyden, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2621 · Cited by 1,300
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006) · Nature Medicine · doi:10.1038/nm1483 · Cited by 1,219
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3023 · Cited by 1,112
Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44
Takaishi, S., Okumura, T., Tu, S., Wang, S. S. W., Shibata, W., Vigneshwaran, R., Gordon, S. A. K., Shimada, Y., & Wang, T. C. (2009) · Stem Cells · doi:10.1002/stem.30 · Cited by 1,039
Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U., & Bell, J. I. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12160 · Cited by 1,015
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
Nieto, M. A. (2013) · Science · doi:10.1126/science.1234850 · Cited by 967
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
Jang, Y.-Y., & Sharkis, S. J. (2007) · Blood · doi:10.1182/blood-2007-05-087759 · Cited by 894
Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
Scheel, C., & Weinberg, R. A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.04.001 · Cited by 881
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
Tsukita, S., Oishi, K., Sato, N., Sagara, J., Kawai, A., & Tsukita, S. (1994) · The Journal of cell biology · doi:10.1083/jcb.126.2.391 · Cited by 779
Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.009 · Cited by 717
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708
Programmable RNA recognition and cleavage by CRISPR/Cas9
O’Connell, M. R., Oakes, B. L., Sternberg, S. H., East-Seletsky, A., Kaplan, M., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13769 · Cited by 632
Brown, R. L., Reinke, L. M., Damerow, M. S., Perez, D., Chodosh, L. A., Yang, J., & Cheng, C. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44540 · Cited by 631
Naor, D., Nedvetzki, S., Golan, I., Melnik, L., & Faitelson, Y. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795574 · Cited by 557
Goldstein, L. A., Zhou, D. F. H., Picker, L. J., Minty, C. N., Bargatze, R. F., Ding, J. F., & Butcher, E. C. (1989) · Cell · doi:10.1016/0092-8674(89)90639-9 · Cited by 555
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., & Holland, E. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.005 · Cited by 540
CD44 is required for two consecutive steps in HGF/c-Met signaling
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P., & Ponta, H. (2002) · Genes & Development · doi:10.1101/gad.242602 · Cited by 518
Godar, S., Ince, T. A., Bell, G. W., Feldser, D., Donaher, J. L., Bergh, J., Liu, A., Miu, K., Watnick, R. S., Reinhardt, F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.006 · Cited by 456
Significance of CD44 gene products for cancer diagnosis and disease evaluation
Matsumura, Y., & Tarin, D. (1992) · The Lancet · doi:10.1016/0140-6736(92)93077-z · Cited by 450
Bennett, K. L., Jackson, D. G., Simon, J. C., Tanczos, E., Peach, R., Modrell, B., Stamenkovic, I., Plowman, G., & Aruffo, A. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.4.687 · Cited by 427
Reactive Oxygen Species in Normal and Tumor Stem Cells
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00001-3 · Cited by 403
The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan.
Culty, M., Nguyen, H. A., & Underhill, C. B. (1992) · The Journal of cell biology · doi:10.1083/jcb.116.4.1055 · Cited by 395
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell
Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G. J., Wada, T., Masuko, T., Mogushi, K., Tanaka, H., et al. (2012) · Nature Communications · doi:10.1038/ncomms1892 · Cited by 383
Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway
Okamoto, I., Kawano, Y., Murakami, D., Sasayama, T., Araki, N., Miki, T., Wong, A. J., & Saya, H. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200108159 · Cited by 372
Bartolazzi, A., Peach, R., Aruffo, A., & Stamenkovic, I. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.53 · Cited by 331
Bourguignon, L. Y. W., Spevak, C. C., Wong, G., Xia, W., & Gilad, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.027466 · Cited by 316
Yu, M., Jambhrunkar, S., Thorn, P., Chen, J., Gu, W., & Yu, C. (2013) · Nanoscale · doi:10.1039/c2nr32145a · Cited by 316
Tijink, B. M., Buter, J., de Bree, R., Giaccone, G., Lang, M. S., Staab, A., Leemans, C. R., & van Dongen, G. A. M. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0910 · Cited by 315
Involvement of CD44, a molecule with a thousand faces, in cancer dissemination
Naor, D., Wallach-Dayan, S. B., Zahalka, M. A., & Sionov, R. V. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.015 · Cited by 309
Bourguignon, L. Y. W., Wong, G., Earle, C., & Chen, L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308528 · Cited by 293
MicroRNA-21 regulates the self-renewal of mouse spermatogonial stem cells
Niu, Z., Goodyear, S. M., Rao, S., Wu, X., Tobias, J. W., Avarbock, M. R., & Brinster, R. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109987108 · Cited by 275
Tamada, M., Nagano, O., Tateyama, S., Ohmura, M., Yae, T., Ishimoto, T., Sugihara, E., Onishi, N., Yamamoto, T., Yanagawa, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3024 · Cited by 275
Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J.-I., Nakao, M., Matsumoto, M., Suga, M., Ando, M., Nakajima, M., & Saya, H. (1999) · Oncogene · doi:10.1038/sj.onc.1202447 · Cited by 257
Use of minigene systems to dissect alternative splicing elements
Cooper, T. A. (2005) · Methods · doi:10.1016/j.ymeth.2005.07.015 · Cited by 248
Bourguignon, L. Y. W., Earle, C., Wong, G., Spevak, C. C., & Krueger, K. (2012) · Oncogene · doi:10.1038/onc.2011.222 · Cited by 239
Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
Tamada, M., Suematsu, M., & Saya, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0859 · Cited by 237
CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches
Williams, K., Motiani, K., Giridhar, P. V., & Kasper, S. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213480714 · Cited by 229
Cheng, W., Liu, T., Wan, X., Gao, Y., & Wang, H. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08589.x · Cited by 229
Bourguignon, L. Y. W., Singleton, P. A., Zhu, H., & Zhou, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204320200 · Cited by 224
Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., Watanabe, M., Beppu, T., Tamada, M., Nagano, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0299 · Cited by 215
Bessède, E., Staedel, C., Acuña Amador, L. A., Nguyen, P. H., Chambonnier, L., Hatakeyama, M., Belleannée, G., Mégraud, F., & Varon, C. (2014) · Oncogene · doi:10.1038/onc.2013.380 · Cited by 210
CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells
Lau, W. M., Teng, E., Chong, H. S., Lopez, K. A. P., Tay, A. Y. L., Salto-Tellez, M., Shabbir, A., So, J. B. Y., & Chan, S. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2309 · Cited by 206
Regulation of alternative splicing of CD44 in cancer
Prochazka, L., Tesarik, R., & Turanek, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.011 · Cited by 198
Location, Location, Location: The Cancer Stem Cell Niche
Sneddon, J. B., & Werb, Z. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.009 · Cited by 197
Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., Onishi, N., Masuko, T., Yoshizawa, K., Kawashiri, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3609-t · Cited by 191
Orian-Rousseau, V., Morrison, H., Matzke, A., Kastilan, T., Pace, G., Herrlich, P., & Ponta, H. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-08-0674 · Cited by 190
Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway
Weg-Remers, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4194 · Cited by 184
Direct reprogramming of stem cell properties in colon cancer cells by CD44
Su, Y., Lai, H., Chang, Y., Chen, G., & Lee, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.211 · Cited by 174
Shah, V., Taratula, O., Garbuzenko, O. B., Taratula, O. R., Rodriguez-Rodriguez, L., & Minko, T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1536 · Cited by 173
A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis
Tremmel, M., Matzke, A., Albrecht, I., Laib, A. M., Olaku, V., Ballmer-Hofer, K., Christofori, G., Héroult, M., Augustin, H. G., Ponta, H., et al. (2009) · Blood · doi:10.1182/blood-2009-04-219204 · Cited by 170
Acetylation and activation of STAT3 mediated by nuclear translocation of CD44
Lee, J.-L., Wang, M.-J., & Chen, J.-Y. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200812060 · Cited by 164
Shi, S., Han, L., Deng, L., Zhang, Y., Shen, H., Gong, T., Zhang, Z., & Sun, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.005 · Cited by 158
Marangoni, E., Lecomte, N., Durand, L., Pinieux, G. D. B. D., Decaudin, D., Chomienne, C., Smadja‐Joffe, F., & Poupon, M. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604953 · Cited by 157
TNF-α Induction of CD44-Mediated Leukocyte Adhesion by Sulfation
Maiti, A., Maki, G., & Johnson, P. (1998) · Science · doi:10.1126/science.282.5390.941 · Cited by 156
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
Krishnamachary, B., Penet, M., Nimmagadda, S., Mironchik, Y., Raman, V., Solaiyappan, M., Semenza, G. L., Pomper, M. G., & Bhujwalla, Z. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044078 · Cited by 145
A positive feedback loop couples Ras activation and CD44 alternative splicingPreprint
Cheng, C., Yaffe, M. B., & Sharp, P. A. (2006) · Genes & Development · doi:10.1101/gad.1430906 · Cited by 144
Bourguignon, L., Shiina, M., & Li, J. J. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800092-2.00010-1 · Cited by 140
Zeilstra, J., Joosten, S. P. J., van Andel, H., Tölg, C., Berns, A. J. M., Snoek, M., van de Wetering, M., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2013) · Oncogene · doi:10.1038/onc.2012.611 · Cited by 140
CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence
Hirata, K., Suzuki, H., Imaeda, H., Matsuzaki, J., Tsugawa, H., Nagano, O., Asakura, K., Saya, H., & Hibi∥, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.314 · Cited by 139
miRNA-708 Control of CD44+ Prostate Cancer–Initiating Cells
Saini, S., Majid, S., Shahryari, V., Arora, S., Yamamura, S., Chang, I., Zaman, M. S., Deng, G., Tanaka, Y., & Dahiya, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0540 · Cited by 130
A hyaluronan synthase suppressor, 4‐methylumbelliferone, inhibits liver metastasis of melanoma cells
Yoshihara, S., Kon, A., Kudo, D., Nakazawa, H., Kakizaki, I., Sasaki, M., Endo, M., & Takagaki, K. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.079 · Cited by 129
Mikami, S., Mizuno, R., Kosaka, T., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29137 · Cited by 114
Perspectives of CD44 targeting therapies
Orian‐Rousseau, V., & Ponta, H. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1424-2 · Cited by 113
Uchino, M., Kojima, H., Wada, K., Imada, M., Onoda, F., Satofuka, H., Utsugi, T., & Murakami, Y. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-414 · Cited by 111
Wang, S. J., Wreesmann, V. B., & Bourguignon, L. (2007) · Head & Neck · doi:10.1002/hed.20544 · Cited by 102
Rupp, U., Schoendorf-Holland, E., Eichbaum, M. H. R., Schütz, F., Lauschner, I., Schmidt, P., Staab, A., Hanft, G., Huober, J., Sinn, H., et al. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32801403f4 · Cited by 99
Bai, Y., Liu, Y.-J., Wang, H., Xu, Y., Stamenkovic, I., & Yu, Q. (2006) · Oncogene · doi:10.1038/sj.onc.1209849 · Cited by 96
Ju, S.-Y., Chiou, S., & Su, Y. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.09.011 · Cited by 92
Delivery of CD44 shRNA/Nanoparticles within Cancer Cells
Misra, S., Hascall, V. C., Giovanni, C. D., Markwald, R. R., & Ghatak, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806772200 · Cited by 89
Signal Transduction via CD44: Role of Plasma Membrane Microdomains
Ilangumaran, S., Borisch, B., & Hoessli, D. C. (1999) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428199909169610 · Cited by 86
Hibino, S., Shibuya, M., Engbring, J. A., Mochizuki, M., Nomizu, M., & Kleinman, H. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0129 · Cited by 76
Peptide-based vaccines for cancer therapy
Parmiani, G., Russo, V. E. A., Maccalli, C., Parolini, D., Rizzo, N., & Maio, M. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29418 · Cited by 74
A Five-Amino-Acid Peptide Blocks Met- and Ron-Dependent Cell Migration
Matzke, A., Herrlich, P. A., Ponta, H., & Orian‐Rousseau, V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0207 · Cited by 73
Zubeldia, I. G., Bleau, A., Redrado, M., Serrano, D., Agliano, A., Gil, C., Vidal‐Vanaclocha, F., Lecanda, J., & Calvo, A. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.11.004 · Cited by 70
Goodarzi, N., Ghahremani, M. H., Amini, M., Atyabi, F., Ostad, S. N., Ravari, N. S., Nateghian, N., & Dinarvand, R. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12288 · Cited by 69
Piotrowicz, R. S., Damaj, B. B., Hachicha, M., Incardona, F., Howell, S. B., & Finlayson, M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0351 · Cited by 68
Bánky, B., Rásó‐Barnett, L., Barbai, T., Tı́már, J., Becságh, P., & Rásó, E. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-83 · Cited by 62
Prognostic significance of CD44 variant 2 upregulation in colorectal cancer
Ozawa, M., Ichikawa, Y., Zheng, Y.-W., Oshima, T., Miyata, H., Nakazawa, K., Guan, H.-B., Shiozawa, M., Akaike, M., Watanabe, K., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.253 · Cited by 61
Katoh, S., Goi, T., Naruse, T., Ueda, Y., Kurebayashi, H., Nakazawa, T., Kimura, Y., Hirono, Y., & Yamaguchi, A. (2015) · PubMed · Cited by 60
CD44 promotes Kras-dependent lung adenocarcinoma
Zhao, P., Damerow, M. S., Stern, P., et al. (2012) · Oncogene · doi:10.1038/onc.2012.542 · Cited by 58
WNT5A Inhibits Metastasis and Alters Splicing of Cd44 in Breast Cancer Cells
Jiang, W. G., Crossman, D. K., Mitchell, E., Sohn, P., Crowley, M. R., & Serra, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058329 · Cited by 56
The prognostic value of CD44 expression in gastric cancer: A meta-Analysis
Chen, Y., Fu, Z., Xu, S., Xu, Y., & Xu, P. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.08.001 · Cited by 55
Internalization of Met Requires the Co-Receptor CD44v6 and Its Link to ERM Proteins
Hasenauer, S., Malinger, D., Koschut, D., Pace, G., Matzke, A., von Au, A., & Orian‐Rousseau, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062357 · Cited by 52
Gold, M. A., Brady, W. E., Lankes, H. A., Rose, P. G., Kelley, J. L., Geest, K. D., Crispens, M. A., Resnick, K. E., & Howell, S. B. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.023 · Cited by 47
Skandalis, S. S., Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800092-2.00011-3 · Cited by 44
Boyd, D. D., Kim, S.-J., Wang, H., Jones, T. R., & Gallick, G. E. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63855-2 · Cited by 43
DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis
Wallach‐Dayan, S. B., Rubinstein, A. M., Hand, C., Breuer, R., & Naor, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2383 · Cited by 39
Ugarte-Berzal, E., Bailón, E., Amigo-Jiménez, I., Albar, J. P., Garcia-Marco, J. A., & Garcı́a-Pardo, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.559187 · Cited by 37
The effects of CD 44 down‐regulation on stem cell properties of head and neck cancer cell lines
Kidwai, F. K., Costea, D. E., Hutchison, I. L., & Mackenzie, I. C. (2013) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12076 · Cited by 33
Li, J., Zha, X., Wang, R., Li, X., Xu, B., Xu, Y., & Yin, Y. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.11.021 · Cited by 28
Fan, C., Wen, L., Qiang, Z.-D., Chen, T., Zhou, Z., Mo, X., & Hu, J. (2012) · PubMed · doi:10.5754/hge10727 · Cited by 24
Cao, X., Cao, D., Jin, M., Jia, Z., Kong, F., Ma, H., Wang, Y., & Jiang, J. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-157 · Cited by 22
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
CD44 as a tumor biomarker and therapeutic target
Xu, H., Niu, M., Yuan, X., Wu, K., & Liu, A. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00192-0 · Cited by 389
Drug resistance and Cancer stem cells
Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-020-00627-5 · Cited by 331
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
Metadata
- Authors
- Yan, Y., Zuo, X., & Wei, D.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-01
- Volume
- 4
- Issue
- 9
- Pages
- 1033-1043
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- OpenAlex
- W2095782040
- Cited by
- 633
- References
- 108
- FWCI
- 20.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.